Sep 21, 2020
I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma
Sep 17, 2020
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer
Sep 08, 2020
I-Mab Announces Upcoming Participation at September Conferences
Sep 04, 2020
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
Sep 04, 2020
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Aug 31, 2020
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update
Aug 17, 2020
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China
Aug 06, 2020
I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020
Aug 04, 2020
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency
Jul 28, 2020
I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer
Jul 15, 2020
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million
May 29, 2020
I-Mab Announces Upcoming Participation at June Conferences
May 21, 2020
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of TJ107/HyLeukin-7(TM) in Glioblastoma Multiforme
May 20, 2020
I-Mab Expands Global Presence with New Hong Kong Office
May 13, 2020
First Patient Dosed with I-Mab's CD73 Antibody TJD5 in Phase 1/2 Clinical Trial in China for Advanced Solid Tumors